top of page
Search

VeinTech Secures USD $750,000 Non-Dilutive Grant from RhodeIsland Life Science Hub to Launch U.S. Commercialization

  • mliddelow
  • Jul 2
  • 3 min read

Perth, Australia / Providence, Rhode Island — 9th June 2025 – Funding Propels Australia-Born

MedTech Startup into Global Spotlight. VeinTech, a rapidly emerging medtech innovator

revolutionizing IV insertion, has been awarded a USD $750,000 non-dilutive grant by the Rhode

Island Life Science Hub as part of its highly competitive New Business Attraction Program. The

funding will support VeinTech's expansion into the United States, including its first U.S. office in

Providence, Rhode Island—accelerating its FDA pathway, limited market release, and manufacturing

scale-up.


The grant forms part of a broader initiative by the RILSH to attract high-impact global healthcare

innovators to Rhode Island and marks a major milestone in VeinTech’s global commercial journey.

This move builds on the Perth Biodesign–New England Medical Innovation Center (NEMIC) alliance,

which initially connected VeinTech with the New England innovation ecosystem and laid the

foundation for the company’s cross-continental expansion.


“Being selected alongside top-tier U.S. medtech companies validates not only our technology but

our global scalability,” said Dr. Nikhilesh Bappoo, CEO and Co-Founder of VeinTech. “This non-

dilutive capital gives us strategic runway to execute critical milestones while preserving value for

investors—something few early-stage companies can offer in the current climate.”


VeinTech’s flagship product empowers any healthcare worker—not just specialists—to confidently

insert IVs with real-time vein visualization. By transforming workforce capability and reducing the

need for advanced training, VeinTech boosts procedural throughput and addresses a deceptively

simple but globally costly problem: failed IV insertions, which affect up to 2 in 3 patients with an

average 40% failure rate and cost billions annually.


"This is not just another medtech startup—VeinTech is one of the hottest early-stage healthtech

companies globally right now," said Chairman Peter Traianou, a global veteran of the medical device

industry. "We're building dual sovereign ultrasound capability in WA and unlocking U.S. market

access—all while building a cross-continental pipeline that starts in Perth and scales globally."


In the face of global trade uncertainty and rising import tariffs, this investment allows VeinTech to

secure U.S.-based production, avoid tariff barriers, and deepen integration with American hospital

networks. With this grant secured, VeinTech is now in the final stages of closing its next $2.5M

round. This grant significantly de-risks the opportunity, offering investors rare alignment of non-

dilutive funding, regulatory momentum, and early-stage international traction. Discussions with

strategics are already underway, and investor demand is growing.


“We are very excited to have VeinTech join our growing Life Science community here in Rhode

Island. We look forward to a strong partnership with the VeinTech team and collaborating to

accelerate their Innovative technology allowing patients and communities in the US to benefit from

this novel medical device” stated Dr. Mark Turco, President and CEO RI Life Science Hub


About VeinTech:

VeinTech is changing the way IV insertions are done—making a tricky, often painful procedure much

easier and more reliable. Our first product, VeinWise, is a portable imaging device that helps any

nurse or healthcare worker find the right vein, first time, every time. We don’t just stop at getting

the needle in—we focus on the whole process of vein access, from choosing the best vein to making

sure the IV stays in place and works properly. VeinTech’s business combines device sales with

recurring consumables. We’ve already raised over USD$4 million and built strong partnerships in

Australia and the U.S. Now, we’re ready to take the next big steps: FDA submission, pilot studies in

U.S. hospitals, and ramping up production. Our mission is simple: help clinicians work smarter and

faster, reduce costs for hospitals, and make patients’ lives a little easier. With our solid plan and

strong momentum, VeinTech is ready to transform vascular access.


About RILSH:

The Life Science Hub positions the state to deliver on a bold vision of transforming Rhode Island into

a globally recognized life science innovation hub by coalescing existing stakeholders, activities, and

investments while building new capabilities. Through an initial three-year, $45 million investment,

the Hub will serve as the central and coordinating organization facilitating the development of

medical advances and scientific breakthroughs by supporting companies that specialize in life

sciences.


Learn more:  

Media Contacts: Nikhilesh Bappoo  Ph +61 406 659 568 E nbappoo@veintech.com.au 

 
 
 

Comments


  • alt.text.label.Twitter
  • alt.text.label.LinkedIn

©2024 VeinTech Pty Ltd

INVESTORS

If you are an interested in learning more about what we do and how you can join us, please reach out on our contact page.

bottom of page